Vowst (Fecal Microbiota Spores, Live-Brpk)
Brand Names: Vowst
Methodology & AI Transparency ⓘ
Vowst (Fecal Microbiota Spores, Live-Brpk) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary fda prescription therapeutic agent presentation registered by Aimmune Therapeutics, Inc., Vowst supplies active moiety Fecal Microbiota Spores, Live-Brpk (cross-referenced at /meds/fecal-microbiota-spores-live-brpk) in 30000000 [CFU]/1 Capsule; 296 mL (NDC 71881-400; SPL 2026-04-23).
- 2 Real-world patient consensus: Registered under RxNorm 2636548 and SPL 2026-04-23, pairing Vowst packaging with active ingredient Fecal Microbiota Spores, Live-Brpk.
- 3 Typical cash cost range: 30-day cash pricing ranges from $172.66 discount cash to $457.55 walk-in retail (NADAC $2.2800/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Vowst (Fecal Microbiota Spores, Live-Brpk): diarrhea (10%), fatigue (22.2%), constipation (14.4%).
Ask our AI Specialists anything about Vowst (Fecal Microbiota Spores, Live-Brpk)
Vowst (Fecal Microbiota Spores, Live-Brpk) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary fda prescription therapeutic agent presentation registered by Aimmune Therapeutics, Inc., Vowst supplies active moiety Fecal Microbiota Spores, Live-Brpk (cross-referenced at /meds/fecal-microbiota-spores-live-brpk) in 30000000 [CFU]/1 Capsule; 296 mL (NDC 71881-400; SPL 2026-04-23). Clinical prescribing and dispensing guidelines focus on 1 Indications and usage vowst: is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in.
The active constituent inside Vowst—Fecal Microbiota Spores, Live-Brpk—functions as a targeted fda prescription therapeutic agent agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Fecal Microbiota Spores, Live-Brpk, Vowst (registered by Aimmune Therapeutics, Inc., SPL 2026-04-23) specifies proprietary packaging (71881-400) and 30000000 [CFU]/1 Capsule; 296 mL quality controls alongside a $2.2800/unit NADAC acquisition baseline.
Pharmacokinetic profiling of Vowst (Fecal Microbiota Spores, Live-Brpk) demonstrates an elimination half-life of Biphasic clearance with 11–23 hr terminal t½ under Vowst (Fecal Microbiota Spores, Live-Brpk) maintenance with Systemic oral bioavailability of roughly 55%–67% following first-pass transit systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (vowst (fecal microbiota spores, live-brpk)), reaching clinical onset within initial pharmacodynamic onset within 1–2 hrs (peak cmax) for vowst (fecal microbiota spores, live-brpk).
Titration schedules for Vowst (Fecal Microbiota Spores, Live-Brpk) (30000000 [CFU]/1 Capsule → 296 mL) require excluding documented intolerance or hypersensitivity reaction involving fecal microbiota spores, live-brpk (fda prescription therapeutic agent); concurrent restricted medications flagged in section 4/7 of the vowst (fecal microbiota spores, live-brpk) dailymed monograph (2636548); real-world patient logs highlight fatigue (22.2% of reports), constipation (14.4% of reports), diarrhea (10% of reports) alongside a 91.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Vowst (Fecal Microbiota Spores, Live-Brpk) (fda prescription therapeutic agent).
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Vowst (Fecal Microbiota Spores, Live-Brpk) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Fecal Microbiota Spores, Live-Brpk (fda prescription therapeutic agent)
- Concurrent restricted medications flagged in Section 4/7 of the Vowst (Fecal Microbiota Spores, Live-Brpk) DailyMed monograph (2636548)
Logged Side-Effect Incidence (6 Reports)
Vowst (Fecal Microbiota Spores, Live-Brpk) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vowst (Fecal Microbiota Spores, Live-Brpk))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Metformin alters the gut microbiome of individuals with treatment-naive type 2 By directly investigating metformin-microbiota interactions in a gut simulator, we showed that metformin affected pathways with common biological functions in species from two different phyla, and many of the... Nature medicine • 2017-07-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 28530702 ↗ |
| Can This Approach Help? Inside the Latest Research on Impact of an oral purified microbiome therapeutic on the gastrointestinal These findings on the pharmacology of VOS underscore the importance of rapidly restoring key protective functions of the microbiome in patients with recurrent CDI to achieve durable prevention of recurrence, as observed in the... Nature medicine • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41491103 ↗ |
| Can This Approach Help? Inside the Latest Research on Microbiome compositional changes and clonal engraftment in a phase 3 trial of This study utilizes data from a large clinical trial to establish a method with high specificity for exploring clonal engraftment from microbiota-based treatments to facilitate future how the body absorbs the medicine and how... Gut microbes • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40552763 ↗ |
| Can This Approach Help? Inside the Latest Research on Microbiome and metabolome changes after fecal microbiota, live-jslm, The microbiota-gut-brain axis is posited to modulate health-related quality of life, microbiome, and metabolome changes through immune, gastrointestinal, and central nervous system functions in patients with recurrent C. Anaerobe • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41115624 ↗ |
| Can This Approach Help? Inside the Latest Research on Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides This analysis provides further evidence of RBL real-world benefits and safety across subgroups, including those at high risk for rCDI. Journal of clinical gastroenterology • 2024-09-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38019088 ↗ |
Vowst (Fecal Microbiota Spores, Live-Brpk) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.2800/unit (~$68.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $457.55 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $172.66 / mo | View logs ↓ |
Vowst (Fecal Microbiota Spores, Live-Brpk) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vowst (Fecal Microbiota Spores, Live-Brpk) RxNorm Concept ID | 2636548 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.2800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $457.55 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $172.66 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vowst (Fecal Microbiota Spores, Live-Brpk) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Vowst (Fecal Microbiota Spores, Live-Brpk) integrating DailyMed SPL (2026-04-23), CMS NADAC ($2.2800/unit), and 6 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vowst (Fecal Microbiota Spores, Live-Brpk) community threads and patient logs by age, biological sex, dosage, and treatment duration.